Avior Wealth Management LLC Has $629,000 Stake in Insulet Co. (NASDAQ:PODD)

Avior Wealth Management LLC reduced its position in Insulet Co. (NASDAQ:PODD) by 16.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,409 shares of the medical instruments supplier’s stock after selling 462 shares during the period. Avior Wealth Management LLC’s holdings in Insulet were worth $629,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of PODD. Dimensional Fund Advisors LP increased its position in shares of Insulet by 10.0% during the second quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock worth $29,618,000 after acquiring an additional 13,351 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Insulet during the 2nd quarter worth approximately $158,000. Beck Bode LLC raised its stake in shares of Insulet by 33.6% in the second quarter. Beck Bode LLC now owns 93,187 shares of the medical instruments supplier’s stock worth $18,805,000 after purchasing an additional 23,426 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Insulet by 36.3% during the second quarter. Pacer Advisors Inc. now owns 6,506 shares of the medical instruments supplier’s stock valued at $1,313,000 after buying an additional 1,734 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Insulet by 148.6% during the second quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock worth $5,911,000 after buying an additional 17,507 shares in the last quarter.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on PODD. Citigroup upped their target price on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Stock Up 1.1 %

Shares of NASDAQ:PODD opened at $280.35 on Friday. The firm has a fifty day moving average of $267.25 and a 200 day moving average of $235.53. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $282.86. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market capitalization of $19.66 billion, a PE ratio of 48.01, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The firm had revenue of $543.90 million during the quarter, compared to analyst estimates of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period in the previous year, the business posted $0.71 EPS. As a group, research analysts anticipate that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.